MARKET

LQDA

LQDA

Liquidia Technologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.79
-0.49
-5.92%
Pre Market: 8.39 +0.6 +7.70% 08:09 07/06 EDT
OPEN
8.49
PREV CLOSE
8.28
HIGH
8.75
LOW
7.71
VOLUME
1.36K
TURNOVER
--
52 WEEK HIGH
12.10
52 WEEK LOW
2.650
MARKET CAP
221.02M
P/E (TTM)
-3.4431
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LQDA stock price target is 35.33 with a high estimate of 41.00 and a low estimate of 25.00.

EPS

LQDA News

More
Liquidia Announces Closing of Public Offering of Common Stock
GlobeNewswire · 3d ago
GNW, WKHS, ZYNE and BE among midday movers
Seeking Alpha - Article · 5d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
Benzinga · 6d ago
GNW, IIPR among premarket losers
Seeking Alpha - Article · 6d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 6d ago
Liquidia Prices 9.375M Share Offering @$8/Share
Liquidia Technologies, Inc. (NASDAQ: LQDA) announced the pricing of an underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts an
Benzinga · 6d ago
Liquidia to Host Conference Call to Provide Update on Recent Announcements
GlobeNewswire · 6d ago
Liquidia Announces Proposed Offering of Common Stock
GlobeNewswire · 6d ago

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About LQDA

Liquidia Technologies, Inc. is a clinical biopharmaceutical company, which is focused on the developing and commercialization of human therapeutics using its PRINT technology. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The Company is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
More

Webull offers kinds of Liquidia Technologies Inc stock information, including NASDAQ:LQDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LQDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LQDA stock methods without spending real money on the virtual paper trading platform.